

Public Declaration of Interests

INSTRUCTIONS

SECTION 1: PERSONAL DETAILS

This form consists of two parts: your **Personal Details** and **Public Declaration of Interests**. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information. Please be advised that once you have submitted and signed the form, the Agency will publish your declaration of interests on its website.

		The state of the state of the state of	

First name:	Jean-Marc	NOTE: Please write your full first name and last name as mentioned on your identity card/passport.
Last name:	Ferran	
Organisation / company	1: Qualiance ApS	
Country ² :	Denmark	
E-mail address:	jmf@qualiance.dk	
Type of activity 3:	Technical Anonymisation Group	

SECTION 2: PUBLIC DECLARATION OF INTERESTS

If you have interests to declare, please click 'Yes' to the relevant questions and provide further information. All questions in this section must be answered. Your declaration will not be accepted if any fields are left empty.

All current and/or past interests from the last 3 years should be declared. In the case of previous employment in a pharmaceutical company in an executive role or lead role in the development of a medicinal product (see section 2.1), please declare all such past interests from your entire career.

I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests in the pharmaceutical industry I have currently (at the time of completion of the form) or have had (in the last 3 years and in case of previous employment in an executive role or lead role in the development of a medicinal product at any stage of my career) are those listed below:

2.1 Employment	2	.1	Em	plo	OV	me	ent	
----------------	---	----	----	-----	----	----	-----	--

No V Yes

Employment with a pharmaceutical company means any form of occupation, part-time or full-time, paid or unpaid, in the company. A pharmaceutical company means any legal or natural person whose focus is to research, develop, manufacture, market and/or distribute medicinal products. This includes companies to which activities relating to the research, development, manufacturing, marketing and maintenance of medicinal products (which might also be carried out in house) are outsourced on a contract basis.

CROs or consultancy companies providing advice or services relating to the above activities, also fall under the definition of a pharmaceutical company. Independent researchers and research organisations including universities and learned societies are excluded from the scope of the definition of a pharmaceutical company.

Employment in a pharmaceutical company in an **executive role** and/or a **lead role** in the development of a medicinal product **AT ANY STAGE OF YOUR CAREER** should be declared.

Cross product responsibility other than an executive role and/or **individual product** responsibility other than lead role in the development of a medicinal product **IN THE LAST 3 YEARS** should be declared.

	-	-			- 48		
4.	-	Co	ns	u	ITa	n	CV

No () Yes ()

Consultancy means provision of advice (including training on a one to one basis) to a pharmaceutical company regardless of contractual arrangements or any form of remuneration. A pharmaceutical company means any legal or natural person whose focus is to research, develop, manufacture, market and/or distribute medicinal products. This includes companies to which activities relating to the research, development, manufacturing, marketing and maintenance of medicinal products (which might also be carried out in house) are outsourced on a contract basis.

Note i: Scientific advice provided by the NCA of a Member State is not considered a consultancy activity. Conference/Seminar attendance is not considered as consultancy but should be mentioned under section 2.4 Financial Interests if subject to a fee/honoraria and if current.

		ncy company (i.e. a professional business offering advice or services to pharmaceutical
companies), please declare this under Section 2	.1 Employment.	
Consultancy		Please click on any of the footnotes for further information.
Time period 1: Current	Past	
From month: 02 From year:	2016	To month: 07 To year: 2017
Name of pharmaceutical company 2 :	Novartis	
C Individual product related 3		
Consultancy		Please click on any of the footnotes for further information.
Time period 1:	Past	
From month: 01 From year:	2010	
Name of pharmaceutical company ² :	Ferring Pharm	naceuticals
C Individual product related ³		
Consultancy		Please click on any of the footnotes for further information.
Time period 1:	Past	
From month: 01 From year:	2017	
Name of pharmaceutical company 2:	Novo Nordisk	
C Individual product related 3		Cross product relates/ general (non product related) 4
Consultancy		Please click on any of the footnotes for further information.
Time period 1: C Current	Past	

To month: 12

To year:

2015

Page 2 of 7

From month: 02

From year: 2015

	Lundbeck	
Individual product related 3		Cross product relates/ general (non product related) 4
Consultancy		Please click on any of the footnotes for further information.
Fime period : Current ?	Past	
From month: 01 From year:	2012	To month: 12 To year: 2015
Name of pharmaceutical company ² :	Johnson & Joh	ınson
← Individual product related ³		Cross product relates/ general (non product related) 4
Consultancy		Please click on any of the footnotes for further information.
Fime period : Current	Past	
From month: 10 From year:	2015	To month: 01 To year: 2016
Name of pharmaceutical company ² :	Pfizer	
C Individual product related 3		
From month: 11 From year:	production or an extensive section of the section o	To month: 12 To year: 2016
Name of pharmaceutical company ² : Individual product related ³	Novo Nordisk	
Consultancy		
20113GICGIIC Y		Please click on any of the footpotes for further information
ime period : C Current G	Past	Please click on any of the footnotes for further information.
	Past	
From month: 03 From year:	2016	To month: 04 To year: 2016
From month: 03 From year: Name of pharmaceutical company ² :		To month: 04 To year: 2016
From month: 03 From year: Name of pharmaceutical company ² : Individual product related ³	2016 Ono Pharmace	To month: 04 To year: 2016
Name of pharmaceutical company ² : Individual product related ³ Product name:	Ono Pharmace	To month: 04 To year: 2016 eutical Cross product relates/ general (non product related) 4
From month: 03 From year: Name of pharmaceutical company ² : (7) Individual product related ³	2016 Ono Pharmace	To month: 04 To year: 2016 eutical Cross product relates/ general (non product related) 4
From month: 03 From year: Name of pharmaceutical company ² : Individual product related ³ Product name: Therapeutic indication:	Ono Pharmace	To month: 04 To year: 2016 eutical Cross product relates/ general (non product related) 4
From month: 03 From year: Name of pharmaceutical company ² : Individual product related ³ Product name:	Ono Pharmace	To month: 04 To year: 2016 eutical Cross product relates/ general (non product related) 4
From month: 03 From year: Name of pharmaceutical company ² : Individual product related ³ Product name: Therapeutic indication:	Ono Pharmace	To month: 04 To year: 2016 eutical Cross product relates/ general (non product related) 4 ux disease

Please click on any of the footnotes for further information.
To month: 03 To year: 2016
•
Cross product relates/ general (non product related) 4
Please click on any of the footnotes for further information.
rease click of any of the foodiotes for farther information.
Cross product relates/ general (non product related) 4
Cross product relatesy general (non product related)

Ono Pharmaceutical

2.3 Strategic advisory role

Name of pharmaceutical company ²:

No ⊘ Yes ○

Strategic advisory role means participation (with a right to vote on/influence the outputs) in a(n) (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. A pharmaceutical company means any legal or natural person whose focus is to research, develop, manufacture, market and/or distribute medicinal products. This includes companies to which activities relating to the research, development, manufacturing, marketing and maintenance of medicinal products (which might also be carried out in house) are outsourced on a contract basis.

Note: Involvement in Data Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.5 Principal investigator. Involvement in clinical research should be listed under section 2.5 Principal investigator or 2.6 Investigator as appropriate.

1 Please select the appropriate response: Current or Past. For activities which are currently on-going (current is interpreted as the time of completion of the form), please indicate the starting date (month/year). If the strategic advisory role is current and is subject to a fee/honoraria (paid directly to you), please also declare this activity under section 2.4 Current financial interests. For activities that are no longer on-going and have been completed, please also provide the end date (month/year). 2 Pharmaceutical company: means any legal or natural person whose focus is to research, develop, manufacture, market and/or distribute medicinal products. This includes companies to which activities relating to the research, development, manufacturing, marketing and maintenance of medicinal products (which might also be carried out in house) are outsourced on a contract basis. CROs or consultancy companies providing advice or services relating to the above activities, fall under the definition of a pharmaceutical company. Legal or natural persons which do not fall within the scope of the above definition but (i) control (i.e. own a majority stake in, or otherwise exercise a significant influence in the decision-making processes of the relevant pharmaceutical company), (ii) are controlled by or (iii) are under common control of a pharmaceutical company are also considered as pharmaceutical companies. Participation in (scientific) advisory board/steering committee, providing advice on product related strategies: Please provide the product name, active substance and as much details as possible regarding the therapeutic indication, in order to allow evaluation of this declared interest. 2.4 Financial interests Financial interests mean any economic stake in a pharmaceutical company including: - CURRENT holding of stocks and shares, stock options, equities, bonds and or partnership interest in the capital of a pharmaceutical company with the exclusion of the holding of financial interests through an investment fund, pension fund and/or interests in non-nominal unit trusts or similar arrangements provided that they are diversified (i.e. not exclusively based on the pharmaceutical sector) and they are independently managed (i.e. the individual has no influence on their financial management). - CURRENT compensation, fees, honoraria, salaries, grant or other funding (including rents, sponsorships and fellowships) paid by a pharmaceutical company to you in a personal capacity, other than payment for or reimbursement of expenses incurred with research work or reimbursement of reasonable expenses directly related to conference/seminar attendance (i.e. accommodation and travel costs). - CURRENT intellectual property rights including patents, trademarks, know-how and/or copyrights relating to a medicinal product owned by you or of which you are directly a beneficiary. (CURRENT is interpreted at time of completion of this form). 2.5 Principal investigator No

✓ Yes

✓ Principal investigator means an investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre pharmaceutical industry instigated/sponsored trial or the leading investigator of a monocentre pharmaceutical industry instigated/sponsored trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial. Involvement in Data Monitoring Committees should be included in this Note: Academic trials and publicly funded research/development initiatives involving pharmaceutical products should be included under section 2.9 Any other interests or facts. 2.6 Investigator No (7) Yes (Investigator means an investigator involved in a pharmaceutical industry instigated/sponsored trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions. Note: Academic trials and publicly funded research/development initiatives involving pharmaceutical products should be included under section 2.9 Any other interests or facts. 2.7 Grant / Funding to organisation/institution No 🕢 Yes 🔘 Grant or other funding to an organisation/institution means any CURRENT funding (other than compensation for services provided, as requested by National Competent Authorities) received from a pharmaceutical company by an organisation/institution to which you belong, or for which you perform any kind of activity, and which is used to support any of your activities whether or not they are related to research work. Any other funding received from a pharmaceutical company by an organisation/institution to which you belong, or for which you perform any kind of activity do not need to be declared. If you want to declare such funding for transparency purposes, please report under 2.9 Any Other Interests or Facts. (CURRENT is interpreted at time of completion of this form). 2.8 Close family member interest No (Yes (

Close family member means first-line member of your family (i.e. a spouse or a partner, children and parents). Interests to be declared include CURRENT employment, consultancy, strategic advisory role and financial interests.

(CURRENT is interpreted at time of completion of this form).

2.9 Any other interests or facts

For transparency purposes, please also provide information on the following activities in this section:

- · Academic trials and publicly funded research/development initiatives involving pharmaceutical products.
- Membership of an Ethics Committee (you do not need to state a list of trials you were involved in)
- If you work in an organisation/institution where your colleagues provide consultancy advice to pharmaceutical companies, but you are not directly involved in the provision of such advice. Examples include employees of Official Medicines Control Laboratories, staff members of academic departments, etc.
- Participation in European societies/research foundations/strategy boards/treatment groups/focus groups, which may be funded in full or in part from unrestricted grants from pharmaceutical companies (not from one single company), with or without involvement of industry participants and which may provide general advice (on development programmes, clinical study design, strategy, etc.) to several pharmaceutical companies (not one particular company) in a specific therapeutic area

Other interest or facts

I have entered into a strategic alliance in January 2017 with d-Wise Inc. (North Carolina) where I contribute as an SME to the design and development of their data de-identification products.

I have recently joined the CTR2 project team representing PhUSE and Health Canada Reference Group for Implementation of Public Release of Clinical Information.

Also note that in the period spanning from 11/2013 to 12/2016, I provided consultancy services to Novo Nordisk (this is mentioned above as cross-product tasks) in the field of data de-identification, study results publication in EudraCT and ClinicalTrials.GOV databases and support with the analysis phase of their Policy 0070 implementation project. The tasks both included development of tools, procedures and training material as well as use of these tools in conducting data de-identification and study results publication across nearly all their products and therapeutic areas.

Should there be any change to the above due to the fact that I acquire additional interests, I shall promptly notify the **European Medicines Agency** and complete a new Declaration of Interests detailing the changes. This declaration does not discharge me from my obligation to declare any potential conflicting interest(s) at the start of any EMA activity in which I participate.

	the information declared on this form is accurate to the best of my knowledge and nd published on the EMA website.	I acknowledge t	that my information will be sto
Full name:	Jean-Marc Ferran	Date:	10/26/17
Signature:	Tan San		